**Table A.1 Statin intensity**

|  |  |  |
| --- | --- | --- |
| **Statin intensity** | **Type of statin\*** | **Dose** |
| **High-intensity** | Atorvastatin | 40 or 80 mg |
|  | Simvastatin | 80 mg |
|  | Rosuvastatin | 20 or 40 mg |
| **Moderate-intensity** | Atorvastatin | 10 or 20 mg |
|  | Fluvastatin | 40 or 80 mg |
|  | Pravastatin | 40 mg |
|  | Rosuvastatin | 5 or 10 mg |
|  | Simvastatin | 20 or 40 mg |
| **Low-intensity** | Atorvastatin | <10 mg |
|  | Fluvastatin | <40 mg |
|  | Pravastatin | <40 mg |
|  | Rosuvastatin | <5 mg |
|  | Simvastatin | <20 mg |

\*Pitavastatin and lovastatin are not available in the Netherlands

**Table A.2 Prior LLT versus LLT at index date**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Treatment at index date** | | | | | | | | | |
|  | **Statins only,** | **Statins only,** | **Statins only,** | **High intensity statin and ezetimibe** | **Moderate intensity statin and ezetimibe** | **Low intensity statin and ezetimibe** | **Ezetimibe only** | **PCSK9 inhibitors** | **Other LLT** | **No current treatment** |
| **high intensity** | **moderate intensity** | **low intensity** | **+/- other LLT** |
|  | N = 8,133 | N = 39,620 | N = 2,711 | N = 785 | N = 696 | N = 85 | N = 897 | N = 61 | N = 513 | N = 845 |
| **Prior treatment** | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
| **High intensity statin only** | 2,814 (35) | 1,069 (3) | 29 (1) | 444 (57) | 20 (3) | 4 (5) | 33 (4) | 1 (2) | 41 (8) | 0 (0) |
| **Moderate intensity statin only** | 3,001 (37) | 18,863 (48) | 808 (30) | 20 (3) | 346 (50) | 1 (1) | 247 (28) | 3 (5) | 175 (34) | 0 (0) |
| **Low intensity statin only** | 64 (1) | 1,198 (3) | 939 (35) | 0 (0) | 0 (0) | 20 (24) | 51 (6) | 0 (0) | 13 (3) | 489 (58) |
| **High intensity statin and ezetimibe** | 160 (2) | 6 (<0.5) | 0 (0) | 68 (9) | 29 (4) | 0 (0) | 28 (3) | 6 (10) | 5 (1) | 0 (0) |
| **Moderate intensity statin and ezetimibe** | 8 (<0.5) | 247 (1) | 2 (<0.5) | 54 (7) | 60 (9) | 8 (9) | 92 (10) | 5 (8) | 4 (1) | 0 (0) |
| **Low intensity statin and ezetimibe** | 2 (<0.5) | 5 (<0.5) | 11 (<0.5) | 0 (0) | 12 (2) | 6 (7) | 33 (4) | 2 (3) | 4 (1) | 3 (<0.5) |
| **Ezetimibe only** | 21 (<0.5) | 136 (<0.5) | 25 (1) | 154 (20) | 184 (26) | 43 (51) | 189 (21) | 17 (28) | 7 (1) | 318 (38) |
| **PCSK9 inhibitors +/- other LLT** | 0 (0) | 0 (0) | 0 (0) | 1 (<0.5) | 1 (<0.5) | 0 (0) | 8 (1) | 22 (36) | 0 (0) | 3 (<0.5) |
| **Other LLT** | 146 (2) | 572 (1) | 33 (1) | 10 (1) | 6 (1) | 1 (1) | 13 (1) | 1 (2) | 205 (40) | 16 (2) |
| **No prior treatmenta** | 1,917 (24) | 17,524 (44) | 864 (32) | 34 (4) | 38 (5) | 2 (2) | 203 (23) | 4 (7) | 59 (12) | 16 (2)b |

LLT = lipid lowering therapy; PCSK9 = protein convertase subtilisin/kexin type 9

a for at least six months; b some patients were included based on LLT starting in 2018 shortly after index date